Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Primary, secondary endpoints met in Phase 2 wet AMD trial ➤ Modifications made to investigational glaucoma treatment device ➤ Positive Phase 1/2 data from clinical trial for treatment of Leber congenital amaurosis ➤ Results from first-in-human study of siRNA treatment for AMD ➤ Possibility of a minimally invasive approach for treating AMD ➤ ASCRS news and events
When performing cataract surgery in patients who have a functioning trabeculectomy, there may be an increased risk of trabeculectomy failure. Two physicians discussed this risk and how to approach these patients.
➤ First patient treated in Phase 2 study of investigational emulsion for glaucoma ➤ FDA issues complete response letter for dry eye drug NDA ➤ FDA meeting minutes issued for BLA submissions of ophthalmic formulation of bevacizumab ➤ Phase 1/2 trial to begin for first-in-class dry AMD therapy ➤ Company merger news ➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported ➤ Phase 2 trial results of gene therapy for diabetic retinopathy ➤ Phase 2 program for tracking glaucoma biomarkers begins ➤ Results from extension study of the first approved treatment for geographic atrophy ➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy ➤ ASCRS news and events
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
➤ Editorial statement on the nomenclature for refractive lenticule extraction procedure ➤ First patient dosed in Phase 1/2 trial evaluating allogenic cell therapy for corneal edema ➤ IND granted to company investigating therapy for geographic atrophy ➤ Licensing agreement to develop neuroprotective drug ➤ Retinal imaging test detects increased risk for type of dementia ➤ ASCRS news and events
➤ Study: large-scale MIGS study ➤ Partnership to advance early disease detection ➤ License agreement to move forward option for cataract surgery sedation ➤ Name change news ➤ ASCRS news and events
➤ FDA approves drop for mydriasis reversal ➤ Inventors of OCT honored with ‘American Nobel Prize’ ➤ Preservative-free latanoprost begins U.S. launch ➤ Enrollment complete in myopia treatment trial ➤ ASCRS news and events
Three ophthalmologists shared their knowledge of malignant glaucoma, why it occurs, its management, and if possible, its prevention. They also discussed some of the misunderstanding that has surrounded this topic.
Manjool Shah, MD, Glaucoma Editor, discussed what topics are covered in the Glaucoma section of the issue and shared a personal story of working with colleagues from NYU’s School of Engineering on ways to evaluate, modify, and potentially design safer surgical devices.
Get the latest ophthalmology news delivered to your inbox every Friday.